指南与共识白血病

费城染色体阳性急性淋巴细胞白血病中e1a2 BCR-ABL1实时定量逆转录PCR检测微小残留病的标准化与共识指南

Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1.
指南 / 共识 · Leukemia · 2019-03-11

EURO-MRD联盟针对Ph+ ALL中e1a2 BCR-ABL1转录本qRT-PCR检测MRD缺乏标准化的问题,报告了标准化结果并制定共识指南。统一使用EAC引物/探针组和中心制备的质粒标准品对减少实验室间变异影响最大。文章提供了常规诊断和多中心临床试验中标准化MRD分析的详细实验室建议。

要点

  • 统一使用EAC引物/探针组和中心制备质粒标准品对减少实验室间变异影响最大。
  • 标准化RNA提取、cDNA合成和循环仪平台未进一步改善结果。
  • 严格应用检测质量技术标准和统一的数据解读与报告标准至关重要。

核心结论

  • 统一使用EAC引物/探针组和中心制备的质粒标准品对减少实验室间变异影响最大,标准化RNA提取、cDNA合成和循环仪平台未进一步改善结果。

研究设计与样本

  • EURO-MRD联盟开展的关于Ph+ ALL中e1a2 BCR-ABL1转录本qRT-PCR标准化的首个结果报告,旨在克服实验室程序和数据解读缺乏标准化的问题。

主要发现

  • 在QC1中,BCR-ABL1/ABL1比值差异在半个对数以内的分析比例在10^-3水平为40/67(60%)和52/67(78%),在10^-4水平为36/67(53%)和53/67(79%)。

关键数值与推荐

  • 统一使用EAC引物/探针组和中心制备的质粒标准品对减少实验室间变异影响最大。
  • 严格应用检测质量技术标准和统一的数据解读与报告标准至关重要。
  • 提供了常规诊断和多中心临床试验中Ph+ ALL标准化MRD分析的详细实验室建议。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Minimal residual disease (MRD) is a powerful prognostic factor in acute lymphoblastic leukemia (ALL) and is used for patient stratification and treatment decisions, but its precise role in Philadelphia chromosome positive ALL is less clear. This uncertainty results largely from methodological differences relating to the use of real-time quantitative PCR (qRT-PCR) to measure BCR-ABL1 transcript levels for MRD analysis. We here describe the first results by the EURO-MRD consortium on standardization of qRT-PCR for the e1a2 BCR-ABL1 transcript in Ph + ALL, designed to overcome the lack of standardisation of laboratory procedures and data interpretation. Standardised use of EAC primer/probe sets and of centrally prepared plasmid standards had the greatest impact on reducing interlaboratory variability. In QC1 the proportion of analyses with BCR-ABL1/ABL1 ratios within half a log difference were 40/67 (60%) and 52/67 (78%) at 10-3 and 36/67 (53%) and 53/67 (79%) at 10-4BCR-ABL1/ABL1. Standardized RNA extraction, cDNA synthesis and cycler platforms did not improve results further, whereas stringent application of technical criteria for assay quality and uniform criteria for data interpretation and reporting were essential. We provide detailed laboratory recommendations for the standardized MRD analysis in routine diagnostic settings and in multicenter clinical trials for Ph + ALL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Pfeifer H, Cazzaniga G, van der Velden VHJ, et al. Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1. Leukemia. 2019. PMID: 30858550. doi:10.1038/s41375-019-0413-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。